Optimizing the delivery of cancer drugs that block angiogenesis.
Level V
Where this comes from
- Record sourced from PubMed, PMID 20371469.
- Also identified by DOI 10.1126/scitranslmed.3000399.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Drugs that block angiogenesis are important components of first-line therapies for a number of human cancers. However, some of these agents have undesirable effects on the patient. Optimal delivery systems must be developed to maximize clinical benefits and minimize adverse effects in cancer patients. In this Perspective, we discuss these drug-related issues and propose ways to optimize antiangiogenic therapy by the development of new drug delivery systems.
Medical subject headings
- Antineoplastic Agents
- Drug Delivery Systems
- Neoplasms
- Neovascularization, Pathologic